Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Breast Neoplasms 461Neoplasms 378Carcinoma, Non-Small-Cell Lung 354Prostatic Neoplasms 294Colorectal Neoplasms 257Lung Neoplasms 225Multiple Myeloma 206Neoplasm Metastasis 164Pancreatic Neoplasms 156Leukemia, Myeloid, Acute 153Ovarian Neoplasms 136Squamous Cell Carcinoma of Head and Neck 130Melanoma 116Carcinoma, Renal Cell 103Stomach Neoplasms 102Carcinoma, Hepatocellular 100Recurrence 98Lymphoma 94Precursor Cell Lymphoblastic Leukemia-Lymphoma 92Head and Neck Neoplasms 91Lymphoma, Non-Hodgkin 86Glioblastoma 85Brain Neoplasms 84Hematologic Neoplasms 83Urinary Bladder Neoplasms 82Triple Negative Breast Neoplasms 81Endometrial Neoplasms 80Lymphoma, Large B-Cell, Diffuse 79Leukemia, Lymphocytic, Chronic, B-Cell 77Uterine Cervical Neoplasms 74

Interventions

alectinib 1Crizotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Endocrine Neoplasia Type 2a × 30 days × Clear all
NCT03194893 2026-05-20

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Hoffmann-La Roche

Phase 3 Active not recruiting
200 enrolled
EndocrineThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Multiple Endocrine Neoplasia Type 2a

Data powered by HemOnc (CC BY 4.0) Colophon âš¡